Study reports first success of targeted therapy in type of non-small cell lung cancer
A novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions ...